NANOLEK is a Russian biopharmaceutical company with its own high-tech complete cycle production corresponding to the GMP and ISO standards and with RUSNANO among the shareholders.
NANOLEK specializes in the production of import-substituting and innovative pharmaceuticals, both in-house developed and invented with the help of international partners, with a focus on the prevention and treatment of socially significant diseases.
Biomedical complex “NANOLEK” includes three independent production buildings. The plant was built and designed from the ground up under the priority areas of the product portfolio:
1) production of solid dosage forms (antiretroviral therapy, oncology and cardiovascular diseases);
2) biotechnology production in syringes and vials.
From the localization of import substituted drugs to the manufacture of domestic innovative drug development.
Nanolek is implementing its strategy in two stages, while adhering to state priorities for the development of the domestic pharmaceutical industry and the Pharma-2020 strategy.
At the first stage (2012-2017), the NANOLEK’s activity was focused on the priorities of the state policy in the field of import substitution and was aimed at localization on the basis of the production site of the company in the Kirov region producing the most popular high-tech medicines, including those never-before-produced in the Russian Federation.
The next stage (2018-2022) will be introducing to market innovative high-tech in-house developed products, the work on which is being conducted in association with leading Russian research institutes and leading foreign research companies.